146 related articles for article (PubMed ID: 37738399)
1. Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma.
Pietrobono S; Sabbadini F; Bertolini M; Mangiameli D; De Vita V; Fazzini F; Lunardi G; Casalino S; Scarlato E; Merz V; Zecchetto C; Quinzii A; Di Conza G; Lahn M; Melisi D
Cancer Res; 2024 Jan; 84(1):118-132. PubMed ID: 37738399
[TBL] [Abstract][Full Text] [Related]
2. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
[TBL] [Abstract][Full Text] [Related]
3. A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression.
Auciello FR; Bulusu V; Oon C; Tait-Mulder J; Berry M; Bhattacharyya S; Tumanov S; Allen-Petersen BL; Link J; Kendsersky ND; Vringer E; Schug M; Novo D; Hwang RF; Evans RM; Nixon C; Dorrell C; Morton JP; Norman JC; Sears RC; Kamphorst JJ; Sherman MH
Cancer Discov; 2019 May; 9(5):617-627. PubMed ID: 30837243
[TBL] [Abstract][Full Text] [Related]
4. TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Kozloff M; Simionato F; Cleverly A; Smith C; Wang S; Man M; Driscoll KE; Estrem ST; Lahn MMF; Benhadji KA; Tabernero J
Cancer Chemother Pharmacol; 2019 May; 83(5):975-991. PubMed ID: 30887178
[TBL] [Abstract][Full Text] [Related]
5. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma.
Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA
Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial.
Chiorean EG; Picozzi V; Li CP; Peeters M; Maurel J; Singh J; Golan T; Blanc JF; Chapman SC; Hussain AM; Johnston EL; Hochster HS
Cancer Med; 2023 Oct; 12(20):20353-20364. PubMed ID: 37840530
[TBL] [Abstract][Full Text] [Related]
7. Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Melisi D; Garcia-Carbonero R; Macarulla T; Pezet D; Deplanque G; Fuchs M; Trojan J; Oettle H; Kozloff M; Cleverly A; Smith C; Estrem ST; Gueorguieva I; Lahn MMF; Blunt A; Benhadji KA; Tabernero J
Br J Cancer; 2018 Nov; 119(10):1208-1214. PubMed ID: 30318515
[TBL] [Abstract][Full Text] [Related]
8. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.
Toste PA; Nguyen AH; Kadera BE; Duong M; Wu N; Gawlas I; Tran LM; Bikhchandani M; Li L; Patel SG; Dawson DW; Donahue TR
Mol Cancer Res; 2016 May; 14(5):437-47. PubMed ID: 26979711
[TBL] [Abstract][Full Text] [Related]
10. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
[TBL] [Abstract][Full Text] [Related]
11. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Nagathihalli NS; Castellanos JA; Shi C; Beesetty Y; Reyzer ML; Caprioli R; Chen X; Walsh AJ; Skala MC; Moses HL; Merchant NB
Gastroenterology; 2015 Dec; 149(7):1932-1943.e9. PubMed ID: 26255562
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
Ikeda M; Takahashi H; Kondo S; Lahn MMF; Ogasawara K; Benhadji KA; Fujii H; Ueno H
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1169-1177. PubMed ID: 28451833
[TBL] [Abstract][Full Text] [Related]
13. The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Rana M; Kansal R; Chaib M; Teng B; Morrrison M; Hayes DN; Stanfill AG; Shibata D; Carson JA; Makowski L; Glazer ES
Mol Carcinog; 2022 Jun; 61(6):549-557. PubMed ID: 35319799
[TBL] [Abstract][Full Text] [Related]
14. A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Sempere LF; Gunn JR; Korc M
Cancer Biol Ther; 2011 Aug; 12(3):198-207. PubMed ID: 21613822
[TBL] [Abstract][Full Text] [Related]
15. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
[TBL] [Abstract][Full Text] [Related]
16. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
Zheng S; Hu C; Lin H; Li G; Xia R; Zhang X; Su D; Li Z; Zhou Q; Chen R
J Exp Clin Cancer Res; 2022 Feb; 41(1):71. PubMed ID: 35189958
[TBL] [Abstract][Full Text] [Related]
17. Two Birds with One Stone: Therapeutic Targeting of IL1α Signaling Pathways in Pancreatic Ductal Adenocarcinoma and the Cancer-Associated Fibroblasts.
Ling J; Chiao PJ
Cancer Discov; 2019 Feb; 9(2):173-175. PubMed ID: 30737215
[TBL] [Abstract][Full Text] [Related]
18. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology.
Feldmann K; Maurer C; Peschke K; Teller S; Schuck K; Steiger K; Engleitner T; Öllinger R; Nomura A; Wirges N; Papargyriou A; Jahan Sarker RS; Ranjan RA; Dantes Z; Weichert W; Rustgi AK; Schmid RM; Rad R; Schneider G; Saur D; Reichert M
Gastroenterology; 2021 Jan; 160(1):346-361.e24. PubMed ID: 33007300
[TBL] [Abstract][Full Text] [Related]
20. Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
Lee JE; Lee P; Yoon YC; Han BS; Ko S; Park MS; Lee YJ; Kim SE; Cho YJ; Lim JH; Ryu JK; Shim S; Kim DK; Jung KH; Hong SS
Biomed Pharmacother; 2023 Jun; 162():114716. PubMed ID: 37086509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
